Clinical Trials
157
22 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1922
Active, not recruiting
13
8.3%
Completed
63
40.1%
Enrolling By Invitation
1
0.6%
Not yet recruiting
8
5.1%
Recruiting
11
7.0%
Terminated
2
1.3%
Unknown
59
37.6%
No approval data available
- Google has mapped all 9 billion possible single-letter genetic changes across the human genome with AlphaGenome Atlas and made the resource openly available to researchers worldwide. - The company reported that AI detected 25% of interval cancers previously missed in mammograms of 175,000 women in a study with Imperial College London and the UK's NHS. - Google's tuberculosis chest X-ray tool has screened over 25,000 X-rays across 40 locations in six nations, while its diabetic retinopathy model has supported more than 1.15 million screenings. - CEO Sundar Pichai framed the work around four focus areas: health, natural disaster and weather resilience, learning, and economic opportunity.
- A cluster-randomized controlled trial involving 367 health facilities and over 2,400 healthcare workers in Uganda demonstrated that the Med Safety smartphone app increased adverse drug reaction reporting by 73% compared to traditional methods. - The trial showed particularly significant results for dolutegravir-related adverse events, with reports nearly doubling among healthcare professionals using the mobile application. - Published in The Lancet Global Health, this landmark study provides empirical validation for digital pharmacovigilance tools in low- and middle-income countries where underreporting of drug safety issues has historically compromised patient safety. - The Med Safety app, originally developed through the European Innovative Medicines Initiative's WEB-RADR project, has been integrated into Uganda's national pharmacovigilance system since 2020.
- Mycovia Pharmaceuticals has enrolled the first participant in the PLATFORM-CM Phase 2 trial evaluating oteseconazole for cryptococcal meningitis treatment. - The open-label randomized trial will involve up to 200 participants across three sites in Uganda, comparing oteseconazole to standard WHO first-line therapy. - Cryptococcal meningitis causes an estimated 152,000 cases and 112,000 deaths annually, representing a critical unmet medical need particularly in HIV patients. - Preclinical studies demonstrate oteseconazole's potency against both fluconazole-sensitive and resistant Cryptococcus strains, targeting fungal CYP51 for cell wall integrity.
- The recent USAID stop-work order has halted critical HIV research and treatment programs in Nigeria and Uganda, affecting millions of patients who depend on aid-funded antiretroviral therapy. - Despite an emergency waiver for "life-saving" humanitarian assistance, many USAID-funded clinics remain closed, with over 200 HIV prevention staff in Uganda placed on administrative leave. - The suspension threatens Africa's progress toward the global "95-95-95" HIV goals, with concerns about medicine stockpiles running out and potential long-term withdrawal of support.
- Uganda's Ministry of Health and WHO have initiated the world's first randomized vaccine trial for Ebola Sudan virus, launching in record time just four days after outbreak confirmation. - The trial evaluates a recombinant VSV vaccine candidate, addressing the critical absence of licensed vaccines for Ebola Sudan strain, with support from global health organizations and research institutions. - Using a ring vaccination strategy, the trial begins with 40 contacts of the first confirmed case, implementing lessons learned from Uganda's 2022 Ebola Sudan outbreak.
